{
    "id": 25327,
    "cites": 26,
    "cited_by": 0,
    "reference": [
        "Afendulis CC, Chernew ME, Kessler DP. The effect of Medicare Advantage on hospital admissions and mortality. Am J Health Econ 2017;3(2):254-79.",
        "Baker, LC. HMOs and fee for service health care expenditures: evidence from Medicare. Journal of Health Economics 1997;16(4): 453-81.",
        "Bao Y, Wen K, Johnson P, Jen PJ, Meisel ZF, et al. Assessing the Impact of State Policies For Prescription Drug Monitoring Programs on High-Risk Opioid Prescriptions. Health Aff. 2018;37(10):1596-1604. Barnett ML, Olenski AR, Thygeson NM, Ishisaka D, Wong S, Jena AB, et al. A health plan\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s formulary led to reduced use of extended-release opioids but did not lower overall opioid use.",
        "Buchmueller TC, Carey C. The effect of prescription drug monitoring programs on opioid utilization in medicare. 2017 NBER Working Paper 23148, available at http://www.nber.org/papers/w23148, accessed September 11, 2018.",
        "Cabral M, Geruso M, Mahoney N. Do Larger Health Insurance Subsidies Benefit Patients or Producers? Evidence from Medicare Advantage. American Econ Review 2018;108(8):2048-87.",
        "Chen JH, Humphreys K, Shah NH, Lembke A. Distribution of opioids by different types of Medicare prescribers. JAMA Int Med. 2016;176(2):259-61.",
        "Chernew M, DeCicca P, Town R. Managed Care and Medical Expenditures of Medicare Beneficiaries. Journal of Health Economics 2008;27(6):1451-61.",
        "Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. AJPH. 2018;108(2):182-6.",
        "Dowell D, Zhang K, Noonan RK, Hockenberry JM. Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Aff. 2016;35(10):1876-83.",
        "Duggan M, Starc A, Vabson B. Who Benefits When the Government Pays More? Pass-through in the Medicare Advantage Program. J Pub Econ 2016;141(1):50-67.",
        "Garcia MC, Dodek AB, Kowalski T, Fallon J, Lee SH, Iademarco MF, et al. Declines in opioid prescribing after a private insurer policy change \u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c Massachusetts 2011-2015, MMWR Morb Mortal Wkly Rep. 2016. 65(41):1125-31.",
        "Guy GP, Zhang K, Bohm MK, Losby J, Lewis B, Young R, et al. Vital signs: changes in opioid prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(26):697704.",
        "HHS OIG. Opioids In Medicare Part D. OEI-02-17-00250, data brief 2017. Available at https://oig.hhs.gov/oei/reports/oei-02-17-00250.pdf, accessed September 11, 2018.",
        "Jena AB, Goldman D, Weaver L, Karaca-Mandic P. Opioid prescribing by multiple providers in Medicare: retrospective observational study of insurance claims. BMJ. 2014;348:1393-1404.",
        "Kaiser Family Foundation. Fact sheet: The Medicare Part D prescription drug benefit. 2017.",
        "Available at https://www.kff.org/medicare/fact-sheet/the-medicare-prescription-drug-benefit-factsheet /, accessed September 10, 2018.",
        "Laverdier D, Pereyda M, Silva J. Changing course: The role of health plans in curbing the opioid epidemic. California Health Care Foundation 2016. Available at https://www.chcf.org/publication/changing-course-the-role-of-health-plans-in-curbing-the-opioidepidemic /, accessed September 10, 2018.",
        "Liu Y, Logan JE, Paulozzi LJ, Zhang K, Jones CM. Potential misuse and inappropriate prescription practices involving opioid analgesics. Am J Man Care. 2013;19(8):648-58.",
        "Paulozzi LJ, Jones CM, Mak KA, Rudd RA. Vital signs: overdoses of prescription opioid pain relievers \u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487-92.",
        "Powell D, Pacula RL, Taylor E. How increasing medical access to opioids contributes to the opioid epidemic: evidence from Medicare Part D. 2015 NBER working paper 21072. Available at http://www.nber.org/papers/w21072, accessed September 11, 2018.",
        "Sacco LN, Duff JH, Sarata AK. Prescription drug monitoring programs. Congressional Research Service 2018 R42593.",
        "Schell M, Currie J. Addressing the Opioid Epidemic: Is There a Role for Physician Education? 2017 NBER Working Paper 23645. Available at htttp://www.nber.org/papers/23645, accessed September 11, 2018.",
        "Starc A, Town RJ. Externalities and benefit design in health insurance. 2018 NBER working paper 21783. Available at http://www.nber.org/papers/21783, accessed September 11, 2018.",
        "UnitedHealth Group, Long-term use of opioid prescriptions and prospects for innovation in prevention, treatment, and pain management. Enterprise Research and Development Clinical Report. 2017. Available at https://www.unitedhealthgroup.com/content/dam/UHG/PDF/2017/UNH-Clinical-InnovationReport -Opioids.pdf?la=en, accessed September 11, 2018.",
        "Wen H, Schackman BR, Aden B, Bao Y. States with prescription drug monitoring mandates saw a reduction in opioids prescribed to Medicaid enrollees. Health Aff. 2017;36(4):733-41.",
        "Zhou C, Florence CS, Dowell D. Payments for opioids shifted substantially to public and private insurers while consumer spending declined, 1999-2012. Health Aff. 2016;35(5);824-31."
    ]
}